Calmodulin kinase IV-dependent CREB activation is required for neuroprotection via NMDA receptor-PSD95 disruption

J Neurochem. 2013 Jul;126(2):274-87. doi: 10.1111/jnc.12176. Epub 2013 Mar 3.

Abstract

NMDA-type glutamate receptors mediate both trophic and excitotoxic signalling in CNS neurons. We have previously shown that blocking NMDAR- post-synaptic density-95 (PSD95) interactions provides significant protection from excitotoxicity and in vivo ischaemia; however, the mechanism of neuroprotection is unclear. Here, we report that blocking PSD-95 interactions with the Tat-NR2B9c peptide enhances a Ca²⁺-dependent protective pathway converging on cAMP Response Element binding protein (CREB) activation. We provide evidence that Tat-NR2B9c neuroprotection from oxygen glucose deprivation and NMDA toxicity occurs in parallel with the activation of calmodulin kinase signalling and is dependent on a sustained phosphorylation of the CREB transcription factor and its activator CaMKIV. Tat-NR2B9c-dependent neuroprotection and CREB phosphorylation are blocked by coapplication of CaM kinase (KN93 and STO-609) or CREB (KG-501) inhibitors, and by siRNA knockdown of CaMKIV. These results are mirrored in vivo in a rat model of permanent focal ischaemia. Tat-NR2B9c application significantly reduces infarct size and causes a selective and sustained elevation in CaMKIV phosphorylation; effects which are blocked by coadministration of KN93. Thus, calcium-dependent nuclear signalling via CaMKIV and CREB is critical for neuroprotection via NMDAR-PSD95 blockade, both in vitro and in vivo. This study highlights the importance of maintaining neuronal function following ischaemic injury. Future stroke research should target neurotrophic and pro-survival signal pathways in the development of novel neuroprotective strategies.

Keywords: NMDA; PSD-95; calcium signaling; calmodulin kinase; neuroprotection; trophic signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology
  • Animals
  • Brain Infarction / etiology
  • Brain Infarction / prevention & control*
  • CREB-Binding Protein / metabolism*
  • Calcium Channel Blockers / pharmacology
  • Calcium-Calmodulin-Dependent Protein Kinase Type 4 / metabolism*
  • Cells, Cultured
  • Cerebral Cortex / cytology
  • Disease Models, Animal
  • Disks Large Homolog 4 Protein
  • Embryo, Mammalian
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology
  • Excitatory Amino Acid Antagonists / pharmacology
  • Glucose / deficiency
  • Hypoxia / pathology
  • In Vitro Techniques
  • Infarction, Middle Cerebral Artery / complications
  • Intracellular Signaling Peptides and Proteins / metabolism*
  • Male
  • Membrane Proteins / metabolism*
  • Neurons / metabolism
  • Nimodipine / pharmacology
  • Phosphorylation
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • Time Factors

Substances

  • Calcium Channel Blockers
  • Disks Large Homolog 4 Protein
  • Dlg4 protein, rat
  • Enzyme Inhibitors
  • Excitatory Amino Acid Antagonists
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Receptors, N-Methyl-D-Aspartate
  • Nimodipine
  • 6-Cyano-7-nitroquinoxaline-2,3-dione
  • CREB-Binding Protein
  • Calcium-Calmodulin-Dependent Protein Kinase Type 4
  • Glucose